Findings

What do systematic reviews say?

25 questions · 27 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 22.2%GRADE not reported 0 · 0%Very low 3 · 11.1%Low 10 · 37%Moderate 8 · 29.6%High 0 · 0%

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 710 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.35, 1.99]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.21, 3.28]
2 studies · 656 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy may leads to higher pain ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 2.44 [1.69, 3.55]
1 study · 596 participants
Low

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 593 participants
Moderate

Laser therapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.57 [0.4, 0.8]
4 studies · 262 participants
Moderate

Laser therapy vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Laser showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1 [0.46, 2.19]
2 studies · 162 participants
Moderate

Laser therapy vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 100 participants
Low

Laser therapy vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endovenous laser ablation (EVLA) vs foam sclerotherapy

Long‐term recurrence (> 5 years) · people with GSV incompetence

It is very uncertain whether endovenous laser ablation (EVLA) changes long‐term recurrence (> 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).

1 finding from 1 review

Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
OR 1.08 [0.4, 2.87]
2 studies · 418 participants
Very low

Endovenous laser ablation (EVLA) vs foam sclerotherapy

Complications (up to 8 years) · people with GSV incompetence

1 finding from 1 review

Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Endovenous laser ablation (EVLA) vs foam sclerotherapy

QoL · people with GSV incompetence

1 finding from 1 review

Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Endovenous laser ablation (EVLA) vs foam sclerotherapy

Technical success · people with GSV incompetence

Endovenous laser ablation (EVLA) showed no clear difference in technical success (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (low certainty).

2 findings from 1 review

Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
OR 6.13 [0.98, 38.27]
3 studies · 588 participants
Low
Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
OR 6.47 [2.6, 16.1]
3 studies · 534 participants
Low

Endovenous laser ablation (EVLA) vs foam sclerotherapy

Recurrence · people with GSV incompetence

It is very uncertain whether endovenous laser ablation (EVLA) changes recurrence (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).

1 finding from 1 review

Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
OR 0.68 [0.2, 2.36]
2 studies · 443 participants
Very low

Endovenous laser ablation (EVLA) vs conventional surgery

Recanalisation or persistence of reflux at 6 weeks · people requiring intervention for short saphenous vein varices

Endovenous laser ablation probably leads to lower recanalisation or persistence of reflux at 6 weeks compared with conventional surgery (moderate certainty).

1 finding from 1 review

Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
OR 0.07 [0.02, 0.22]
3 studies · 289 participants
Moderate